Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Caen cedex, France Clinical Trials

A listing of Caen cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (12) clinical trials

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Due to anti-arrhythmic pharmacological drugs failure to suppress atrial fibrillation (AF), interest towards preventive pacing treatments is increasing. The importance of this option in the panoply of the preventive tools is fully justified, only by considering the insufficiency, the complexity, or the poor reproducibility of the other non-pharmaceutical approaches. Preventive ...

Phase

0.0 miles

Learn More »

Oral Anticoagulation in Haemodialysis Patients

Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines for the hemodialysis patients with atrial fibrillation, the general guidelines apply. However, several retrospective studies suggest that these patients do not benefit from ...

Phase

0.0 miles

Learn More »

Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.

BK virus nephropathy (BKVN), a consequence of the strong immunosuppressive therapy given after kidney transplantation, represents a growing problem in the kidney transplant (KT) setting. In recent cohorts, BKVN concerns up to 10% of kidney transplant recipients and early signs of BK virus (BKV) infection as development of asymptomatic viruria ...

Phase

0.0 miles

Learn More »

EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin

Primary objective : To demonstrate that a daily weight-based low dose of rifampicin is non-inferior to a high dose in the treatment of susceptible Staphylococcus spp. osteo-articular infections. Secondary objectives : To compare, in the two treatment groups (weight-based low dose rifampicin versus weight-based high dose): Possible failure rates (when ...

Phase

0.0 miles

Learn More »

Walking Estimated Limitation Calculated by History - Study 2

Two questionnaires the WELCH and the "walking impairment questionnaire" (WIQ) are submitted to patients referred for vascular investigations for suspcted peripheral arterial disease (PAD). Comparison of score to hemodynamic parameters (first goal) or maximal walking distance (MWD) on treadmill (secondary goal). Scoring of the WIQ is performed according to references. ...

Phase

0.0 miles

Learn More »

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE). Both doses are recommended doses in the 2012 guidelines of the American College of Chest Physicians (ACCP), but it is not known which dose is ...

Phase

0.0 miles

Learn More »

Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder

Inclusions are performed by any previously-labeled baclofen-prescribing physician in the Hauts-de-France or Normandie French regions. INITIAL ASSESSMENT PHONE CALLS In the 15 days following the inclusion, participants will receive two successive phone calls. The first call will be performed by a physician investigator of the study who will: re-explain the ...

Phase

0.0 miles

Learn More »

Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia

B-acute lymphoblastic leukaemia (ALL) is the most common childhood malignancy. Despite enhancement of childhood B-ALL outcome, relapses remain difficult to treat. Several studies in adult acute myeloid leukaemia have shown that proliferation of immunosuppressive cells -particularly T regulatory (Treg) cells and deficient natural killer (NK) cells- was associated with poor ...

Phase

0.0 miles

Learn More »

A Study to Provide Complementary Efficacy Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting

This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days ...

Phase

0.0 miles

Learn More »

Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET

NUMBER OF PATIENTS: 200 patients INCLUSION PERIOD: 33 months STUDY DURATION: 57 months MAIN EVALUATION Primary endpoints Week 10-54: proportion of patients in CCR and with MH (endoscopic Mayo score of 0 or 1) at week 54 Data base lock, data analysis and display (publication) will happen when all included ...

Phase

0.0 miles

Learn More »